Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Donitriptan (Pierre Fabre).

M Dukat1

  • 1Department of Medicinal Chemistry, School of Pharmacy, Medical College of Virginia Campus/Virginia Commonwealth University, Richmond 23298-0540, USA. mdukat@gems.vcu.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|September 29, 2001
PubMed
Summary

Pierre Fabre is developing donitriptan, a novel 5-HT1D agonist, for migraine treatment. Early trials show donitriptan possesses greater potency and intrinsic activity than existing tryptamine derivatives.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Binding of nicotine and homoazanicotine analogues at neuronal nicotinic acetylcholinergic (nACh) receptors.

Bioorganic & medicinal chemistry letters·2003
Same author

Homoazanicotine: a structure-affinity study for nicotinic acetylcholine (nACh) receptor binding.

Journal of medicinal chemistry·2002
Same author

1-[2-methoxy-5-(3-phenylpropyl)]-2-aminopropane unexpectedly shows 5-HT(2A) serotonin receptor affinity and antagonist character.

Journal of medicinal chemistry·2001
Same author

The binding of arylguanidines at 5-HT(3) serotonin receptors: a structure-affinity investigation.

Bioorganic & medicinal chemistry letters·2001
Same author

Imidazoline-modified benzylimidazolines as h5-HT(1D/1B) serotonergic ligands.

Bioorganic & medicinal chemistry·2001
Same author

Chain-lengthened and imidazoline analogues of nicotine.

Bioorganic & medicinal chemistry letters·2000

Area of Science:

  • Pharmacology
  • Neurology
  • Drug Development

Background:

  • Migraine is a debilitating neurological disorder.
  • Current treatments include tryptamine derivatives like sumatriptan.
  • There is a need for more effective migraine therapies.

Purpose of the Study:

  • To introduce donitriptan, a novel 5-HT1D agonist.
  • To highlight donitriptan's development status and pharmacological profile.

Main Methods:

  • Donitriptan is a piperazide 5-HT1D agonist.
  • Phase I trials for migraine have been completed.
  • Phase II development is planned.

Main Results:

  • Donitriptan demonstrates increased potency compared to existing treatments.
  • It exhibits markedly higher intrinsic activity than naratriptan, zolmitriptan, and sumatriptan.

Conclusions:

  • Donitriptan represents a promising new therapeutic candidate for migraine.
  • Its superior pharmacological properties warrant further clinical investigation.

Related Experiment Videos